On the stock market since 1989, it operates in the world of health and science. It has 159 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 8% a year on average.
Sales run at $96.2M a year. A small number, but proof the product has real buyers.
There is $88.9M in the vault; even if every debt were paid off, $71.0M would remain.
A loss of $12.1M against $96.2M in annual sales.
Over the last 12 months, executives reported 91 sells against just 18 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, BLFS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BLFS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.